Corvus Pharmaceuticals Inc [CRVS] stock prices are up 12.75% to $8.05 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CRVS shares have gain 18.56% over the last week, with a monthly amount glided 1.39%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Corvus Pharmaceuticals Inc [NASDAQ: CRVS] stock has seen the most recent analyst activity on October 13, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $16. Previously, H.C. Wainwright started tracking the stock with Buy rating on January 02, 2025, and set its price target to $11. On August 18, 2023, Oppenheimer initiated with an Outperform rating and assigned a price target of $7 on the stock. Cantor Fitzgerald initiated its recommendation with an Overweight and recommended $10 as its price target on May 27, 2021. Mizuho downgraded its rating to Neutral for this stock on February 10, 2021, and downed its price target to $4. In a note dated September 12, 2019, Mizuho initiated a Buy rating.
The stock price of Corvus Pharmaceuticals Inc [CRVS] has been fluctuating between $2.54 and $9.60 over the past year. Currently, Wall Street analysts expect the stock to reach $14.5 within the next 12 months. Corvus Pharmaceuticals Inc [NASDAQ: CRVS] shares were valued at $8.05 at the most recent close of the market. An investor can expect a potential return of 80.12% based on the average CRVS price forecast.
Analyzing the CRVS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.26 and Total Capital is -0.54. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Corvus Pharmaceuticals Inc [NASDAQ:CRVS]’s Current Ratio is 8.29. As well, the Quick Ratio is 8.29, while the Cash Ratio is 0.36.
Transactions by insiders
Recent insider trading involved ORBIMED ADVISORS LLC, Director, that happened on Jun 27 ’25 when 1.18 million shares were sold. Director, Thompson Peter A. completed a deal on Jun 27 ’25 to sell 1.18 million shares.
